Stewart G Albert1, John E Morley1,2. 1. Department of Internal Medicine, Division of Endocrinology, Saint Louis University School of Medicine, St. Louis, MO, USA. 2. Department of Internal Medicine, Division of Geriatrics, Saint Louis University School of Medicine, St. Louis, MO, USA.
Abstract
BACKGROUND: Although male hypogonadism is associated with increased cardiovascular events (CVE), recent concerns are that testosterone supplementation may increase CVE. The purpose was to determine associations with age, initiation or mode of therapy to explain these discrepancies. DATA SYNTHESIS: Meta-analyses were supplemented through Scopus and PubMed with search terms 'testosterone', 'random' and 'trial'. CVE, defined before data extraction, were death, myocardial infarction, acute coronary syndrome, percutaneous coronary intervention, coronary bypass, syncope, arrhythmia, hospital admission for congestive heart failure or cerebrovascular event. RESULTS: There were 45 trials with 5328 subjects evaluated, with a mean age of 63·3 (SD ±7·9) years, followed for mean study duration of 10·6 (± 8·6) months. Overall, testosterone supplementation was not associated with increased CVE risk ratio (rr = 1·10 (95% CI 0·86; 1·41, P = 0·45)). However, there was an increase event rate during the first 12 months (rr = 1·79 (1·13;2·83, P = 0·012)), predominantly in those ≥65 years, (rr = 2·90 (1·35;6·21, P = 0·006)). Within studies with lipid data, CVE were associated with fall in HDL, P = 0·002. Intramuscular testosterone appeared neutral for CVE (rr = 0·96 (0·462;1·98, P = 0·91)) compared with oral testosterone (rr = 2·28 (95% CI 2·28;8·59, P = 0·22)) and transdermal testosterone (rr = 2·80 (1·38;5·68, P = 0·004)). Intramuscular testosterone had the least effect of lowering HDL and non-HDL cholesterol (both P < 0·001). CONCLUSIONS: Testosterone supplementation may be associated with increased CVE in those ≥65 years especially during the first year. Biological actions may differ depending upon mode of testosterone administration with intramuscular testosterone having less cardiovascular risk.
BACKGROUND: Although male hypogonadism is associated with increased cardiovascular events (CVE), recent concerns are that testosterone supplementation may increase CVE. The purpose was to determine associations with age, initiation or mode of therapy to explain these discrepancies. DATA SYNTHESIS: Meta-analyses were supplemented through Scopus and PubMed with search terms 'testosterone', 'random' and 'trial'. CVE, defined before data extraction, were death, myocardial infarction, acute coronary syndrome, percutaneous coronary intervention, coronary bypass, syncope, arrhythmia, hospital admission for congestive heart failure or cerebrovascular event. RESULTS: There were 45 trials with 5328 subjects evaluated, with a mean age of 63·3 (SD ±7·9) years, followed for mean study duration of 10·6 (± 8·6) months. Overall, testosterone supplementation was not associated with increased CVE risk ratio (rr = 1·10 (95% CI 0·86; 1·41, P = 0·45)). However, there was an increase event rate during the first 12 months (rr = 1·79 (1·13;2·83, P = 0·012)), predominantly in those ≥65 years, (rr = 2·90 (1·35;6·21, P = 0·006)). Within studies with lipid data, CVE were associated with fall in HDL, P = 0·002. Intramuscular testosterone appeared neutral for CVE (rr = 0·96 (0·462;1·98, P = 0·91)) compared with oral testosterone (rr = 2·28 (95% CI 2·28;8·59, P = 0·22)) and transdermal testosterone (rr = 2·80 (1·38;5·68, P = 0·004)). Intramuscular testosterone had the least effect of lowering HDL and non-HDL cholesterol (both P < 0·001). CONCLUSIONS:Testosterone supplementation may be associated with increased CVE in those ≥65 years especially during the first year. Biological actions may differ depending upon mode of testosterone administration with intramuscular testosterone having less cardiovascular risk.
Authors: Tom E Nightingale; Pamela Moore; Joshua Harman; Refka Khalil; Ranjodh S Gill; Teodoro Castillo; Robert A Adler; Ashraf S Gorgey Journal: J Spinal Cord Med Date: 2017-08-03 Impact factor: 1.985
Authors: Andrea Salonia; Giulia Rastrelli; Geoffrey Hackett; Stephanie B Seminara; Ilpo T Huhtaniemi; Rodolfo A Rey; Wayne J G Hellstrom; Mark R Palmert; Giovanni Corona; Gert R Dohle; Mohit Khera; Yee-Ming Chan; Mario Maggi Journal: Nat Rev Dis Primers Date: 2019-05-30 Impact factor: 52.329
Authors: Jemma Hudson; Moira Cruickshank; Richard Quinton; Lorna Aucott; Magaly Aceves-Martins; Katie Gillies; Shalender Bhasin; Peter J Snyder; Susan S Ellenberg; Mathis Grossmann; Thomas G Travison; Emily J Gianatti; Yvonne T van der Schouw; Marielle H Emmelot-Vonk; Erik J Giltay; Geoff Hackett; Sudarshan Ramachandran; Johan Svartberg; Kerry L Hildreth; Kristina Groti Antonic; Gerald B Brock; J Lisa Tenover; Hui Meng Tan; Christopher Ho Chee Kong; Wei Shen Tan; Leonard S Marks; Richard J Ross; Robert S Schwartz; Paul Manson; Stephen Roberts; Marianne Skovsager Andersen; Line Velling Magnussen; Rodolfo Hernández; Nick Oliver; Frederick Wu; Waljit S Dhillo; Siladitya Bhattacharya; Miriam Brazzelli; Channa N Jayasena Journal: Lancet Healthy Longev Date: 2022-06
Authors: Carlos Martinez; Samy Suissa; Stephan Rietbrock; Anja Katholing; Ben Freedman; Alexander T Cohen; David J Handelsman Journal: BMJ Date: 2016-11-30